Ionis Pharma Files 8-K on Financial Condition
Ticker: IONS · Form: 8-K · Filed: Feb 21, 2024 · CIK: 874015
Sentiment: neutral
Topics: financial-condition, 8-K, corporate-filing
TL;DR
**Ionis Pharma just dropped an 8-K on its financials, so keep an eye out for their earnings details.**
AI Summary
Ionis Pharmaceuticals Inc. filed an 8-K on February 21, 2024, to report on its results of operations and financial condition. The filing, under SEC File Number 000-19125, indicates that the company, based in Carlsbad, CA, is providing current information as required by the Securities Exchange Act of 1934. This 8-K specifically addresses Item 2.02, Results of Operations and Financial Condition, and Item 9.01, Financial Statements and Exhibits.
Why It Matters
This filing provides investors with updated information on Ionis Pharmaceuticals' financial performance, which can influence stock valuation and future investment decisions.
Risk Assessment
Risk Level: low — This is a routine filing for reporting financial results and does not inherently indicate new risks.
Key Numbers
- 2024-02-21 — Filing Date (Date the 8-K was filed with the SEC)
- 000-19125 — SEC File Number (Unique identifier for the company's SEC filings)
- 874015 — CIK (Central Index Key for Ionis Pharmaceuticals Inc.)
Key Players & Entities
- IONIS PHARMACEUTICALS INC (company) — Registrant
- February 21, 2024 (date) — Date of earliest event reported and filing date
- 000-19125 (dollar_amount) — Commission File No.
- 2855 Gazelle Court Carlsbad , CA 92010 (company) — Address of Principal Executive Offices
- 760-931-9200 (dollar_amount) — Registrant's telephone number
FAQ
What is the purpose of this 8-K filing by Ionis Pharmaceuticals Inc.?
The 8-K filing by Ionis Pharmaceuticals Inc. is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically addressing Item 2.02, Results of Operations and Financial Condition, and Item 9.01, Financial Statements and Exhibits.
When was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was February 21, 2024.
What is the business address and phone number of Ionis Pharmaceuticals Inc. as stated in the filing?
The business address of Ionis Pharmaceuticals Inc. is 2855 Gazelle Court, Carlsbad, CA 92010, and its telephone number is (760) 931-9200.
Under which SEC Act was this 8-K filed?
This 8-K was filed under the 1934 Act, specifically the Securities Exchange Act of 1934.
What is the Central Index Key (CIK) for Ionis Pharmaceuticals Inc.?
The Central Index Key (CIK) for Ionis Pharmaceuticals Inc. is 0000874015.
Filing Stats: 627 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2024-02-21 11:17:25
Filing Documents
- ef20022046_8k.htm (8-K) — 27KB
- ef20022046_ex99-1.htm (EX-99.1) — 387KB
- image0.jpg (GRAPHIC) — 8KB
- image1.jpg (GRAPHIC) — 1KB
- 0001140361-24-008700.txt ( ) — 584KB
- ions-20240221.xsd (EX-101.SCH) — 4KB
- ions-20240221_lab.xml (EX-101.LAB) — 22KB
- ions-20240221_pre.xml (EX-101.PRE) — 16KB
- ef20022046_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On February 21, 2024, Ionis Pharmaceuticals, Inc. (the " Company ") issued a press release announcing the Company's financial results for the quarter and fiscal year ended December 31, 2023. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (" GAAP "), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equity awards and the related tax effects. In addition, in 2022, the Company's non-GAAP net loss excluded the gain on real estate assets related to the Company's sale and leaseback transaction and the related tax effects. The Company is presenting pro forma information with such exclusions because the Company believes it is useful for investors in assessing the Company's operating results compared to the prior year. A copy of the release is furnished with this report as an exhibit pursuant to "Item 2.02. Results of Operations and Financial Condition" of Form 8-K in accordance with SEC Release Nos. 33-8216 and 34-47583. The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the " Exchange Act ") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated February 21, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Ionis Pharmaceuticals, Inc. Dated: February 21, 2024 By: /s/ Patrick R. O'Neil Patrick R. O'Neil Executive Vice President, Chief Legal Officer and General Counsel